about
Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discoveryTargeting BET bromodomains for cancer treatmentStructure-Based Design of an in Vivo Active Selective BRD9 InhibitorDrug Discovery Targeting Bromodomain-Containing Protein 4.Readers of histone methylarginine marks.Bromodomain protein 4 is a novel predictor of survival for gastric carcinomaThe promise and peril of chemical probes.Development of novel cellular histone-binding and chromatin-displacement assays for bromodomain drug discoveryMolecular docking and dynamics simulation study of flavonoids as BET bromodomain inhibitors.Validation of an enantioselective LC-MS/MS method to quantify enantiomers of (±)-OTX015 in mice plasma: Lack of in vivo inversion of (-)-OTX015 to its antipode.BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cellsInduction of USP17 by combining BET and HDAC inhibitors in breast cancer cellsThe SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies.Structure-Guided Design of IACS-9571, a Selective High-Affinity Dual TRIM24-BRPF1 Bromodomain Inhibitor.The BET inhibitor OTX015 reactivates latent HIV-1 through P-TEFb.Epigenetics in cancer stem cells.Selective Inhibition of CBX6: A Methyllysine Reader Protein in the Polycomb FamilyDiscovery of a PCAF Bromodomain Chemical Probe.Discovery and Characterization of GSK2801, a Selective Chemical Probe for the Bromodomains BAZ2A and BAZ2B.Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML).Progress in the Development of non-BET Bromodomain Chemical Probes.BET inhibitors in cancer therapeutics: a patent review.NUT carcinoma in children and adults: A multicenter retrospective study.Identification of a Chemical Probe for Family VIII Bromodomains through Optimization of a Fragment Hit1,3-Dimethyl Benzimidazolones Are Potent, Selective Inhibitors of the BRPF1 Bromodomain.Inhibitors of BRD4 as Potential Cancer Therapy.GSK6853, a Chemical Probe for Inhibition of the BRPF1 BromodomainBET inhibitors RVX-208 and PFI-1 reactivate HIV-1 from latency.Chemical probes and inhibitors of bromodomains outside the BET family.Design, Synthesis, and Biological Activity of 1,2,3-Triazolobenzodiazepine BET Bromodomain Inhibitors.Synthesis and biological evaluation of indazole-4,7-dione derivatives as novel BRD4 inhibitors.Metabolically Derived Lysine Acylations and Neighboring Modifications Tune the Binding of the BET Bromodomains to Histone H4.What is the future of bromodomains in targeted drug development?Discovery of a PCAF Bromodomain Chemical ProbeMolecular Docking Study Characterization of Rare Flavonoids at the Nac-Binding Site of the First Bromodomain of BRD4 (BRD4 BD1)
P2860
Q28260105-00D03314-C460-4938-B511-85291721BD69Q28263519-01C0ADB5-8452-4DC7-9173-39AC8835867FQ28829832-3B46AC05-A3CB-442A-93FF-D5D94E64199AQ30352390-ADECB1F2-93F1-4CFD-B528-7818D079E4B5Q30359633-154090E6-C828-4E68-9A63-6C49AE36F358Q33761645-D0B7D8DF-23DC-4E35-AA2A-1AC40619B14EQ34486195-A08C218D-F2F2-4EA4-9E80-2A9A9F15133AQ36082984-609B497D-2CD1-4BBD-9BA2-40BD90B68BF3Q36096159-95B99BF4-2733-4968-B50E-1ECFA5EC10D4Q36134751-350025D7-7B3F-4DC2-AFDF-2787531E50DAQ36232141-A1F77699-7EF5-4DFC-B33C-9A5F6CB1F8EBQ36545233-2DA33F90-53B8-430A-BF8A-B1E28BBD7D0DQ36584337-86EAB1AF-8E6E-41F1-B521-DE26CD02F5AAQ36586506-1F954112-97D2-4215-9010-92D5E95DE14BQ36790027-DD4D708D-BE9E-4F72-B4AE-86DCC4BAEF2FQ37618640-A1CDDE9B-C163-44E0-84FE-672093C846C6Q38434032-561C2CA4-1DFA-408B-89A9-EE99F43E4866Q38434399-09434B7B-461F-44F4-9710-4DDEF77A6D3DQ38668661-04AC3F02-E1B5-4189-82C4-B2C74C272CB5Q38679327-56D4D19F-AFDC-44B3-A57B-61B09C932057Q38691377-1A2A8307-BB66-44A1-84D8-AEB6CAC7C26EQ38753987-256E3359-9B51-41A9-8A3B-238422640CF7Q39393379-EC9F912C-C663-482B-A895-8716AC2153F4Q39821089-CFAE4871-D7DA-410A-BB25-1A5EE589BAF1Q42198254-6CA088B0-9152-43EA-8DC1-22AF88BEABAFQ42358764-23AAF951-C7F0-4A69-A975-B0850E0D976EQ42732843-E2B0F907-3FB4-4986-B6EC-5289597AAC8FQ47120827-01A7EBA9-0E0D-4E10-8B01-48D051A20E48Q47128083-D7C39572-83D9-4BD4-81BB-534F2B9A69EFQ47272627-E6A943C8-AFC7-42F8-909D-777D00BE167AQ47441188-216EB5B1-703B-46AC-9163-F490C83DD1E8Q47748164-C9771AF3-7DF1-49CE-A009-80C9405C4598Q48808733-1C4781EF-EE10-4BF3-AD46-F9811F17D6FBQ57826915-58E34438-3ECA-43C6-8827-FFAE139C3A0BQ59104243-6B0D3B67-2F54-434E-B666-4D4345F8702D
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
BET bromodomain inhibitors: a patent review.
@ast
BET bromodomain inhibitors: a patent review.
@en
BET bromodomain inhibitors: a patent review.
@nl
type
label
BET bromodomain inhibitors: a patent review.
@ast
BET bromodomain inhibitors: a patent review.
@en
BET bromodomain inhibitors: a patent review.
@nl
prefLabel
BET bromodomain inhibitors: a patent review.
@ast
BET bromodomain inhibitors: a patent review.
@en
BET bromodomain inhibitors: a patent review.
@nl
P2860
P1476
BET bromodomain inhibitors: a patent review.
@en
P2093
Jean-Marc Garnier
P2860
P304
P356
10.1517/13543776.2014.859244
P407
P577
2013-11-22T00:00:00Z